Abstract
Patients and methods: Patients with metastatic solid tumors who had progressed on at least one line of standard of care therapy were referred to the Indiana University Health Precision Genomics Program. Tumor samples were submitted for DNA & RNA next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry for actionable targets. A multi-disciplinary tumor board reviewed all results. For each patient, the ratio of progression-free survival (PFS) of the genomically guided line of therapy divided by the PFS of their prior line was calculated. Patients whose PFS ratio was ≥ 1.3 were deemed to have a meaningful improvement in PFS. Results: From April 2014-October 2015, 168 patients were evaluated and 101 patients achieved adequate clinical follow-up for analysis. 19 of 44 (43.2%) patients treated with genomically guided therapy attained a PFS ratio ≥ 1.3 vs. 3 of 57 (5.3%) treated with non-genomically guided therapy (p < 0.0001). Similarly, overall PFS ratios (irrespective of cutoff) were higher for patients with genomically guided therapy vs non-genomically guided therapy (p = 0.05). Further, patients treated with genomically guided therapy had a superior median PFS compared to those treated with non-genomically guided therapy (86 days vs. 49 days, p = 0.005, H.R. = 0.55, 95% C.I.:0.37-0.84). Conclusion: Patients with refractory metastatic cancer who receive genomically guided therapy have improved PFS ratios and longer median PFS compared to patients who do not receive genomically guided therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 56491-56500 |
| Number of pages | 10 |
| Journal | Oncotarget |
| Volume | 7 |
| Issue number | 35 |
| DOIs | |
| State | Published - 2016 |
Fingerprint
Keywords
- Genomics
- Next-generation sequencing
- Personalized medicine
- Precision medicine
ASJC Scopus subject areas
- Oncology
Cite this
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. / Radovich, Milan; Kiel, Patrick J.; Nance, Stacy M.; Niland, Erin E.; Parsley, Megan E.; Ferguson, Meagan E.; Jiang, Guanglong; Ammakkanavar, Natraj R.; Einhorn, Lawrence; Cheng, Liang; Nassiri, Mehdi; Davidson, Darrell; Rushing, Daniel A.; Loehrer, Patrick; Pili, Roberto; Hanna, Nasser; Thomas Callaghan, J.; Skaar, Todd; Helft, Paul; Shahda, Safi; O'Neil, Bert H.; Schneider, Bryan.
In: Oncotarget, Vol. 7, No. 35, 2016, p. 56491-56500.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers
AU - Radovich, Milan
AU - Kiel, Patrick J.
AU - Nance, Stacy M.
AU - Niland, Erin E.
AU - Parsley, Megan E.
AU - Ferguson, Meagan E.
AU - Jiang, Guanglong
AU - Ammakkanavar, Natraj R.
AU - Einhorn, Lawrence
AU - Cheng, Liang
AU - Nassiri, Mehdi
AU - Davidson, Darrell
AU - Rushing, Daniel A.
AU - Loehrer, Patrick
AU - Pili, Roberto
AU - Hanna, Nasser
AU - Thomas Callaghan, J.
AU - Skaar, Todd
AU - Helft, Paul
AU - Shahda, Safi
AU - O'Neil, Bert H.
AU - Schneider, Bryan
PY - 2016
Y1 - 2016
N2 - Patients and methods: Patients with metastatic solid tumors who had progressed on at least one line of standard of care therapy were referred to the Indiana University Health Precision Genomics Program. Tumor samples were submitted for DNA & RNA next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry for actionable targets. A multi-disciplinary tumor board reviewed all results. For each patient, the ratio of progression-free survival (PFS) of the genomically guided line of therapy divided by the PFS of their prior line was calculated. Patients whose PFS ratio was ≥ 1.3 were deemed to have a meaningful improvement in PFS. Results: From April 2014-October 2015, 168 patients were evaluated and 101 patients achieved adequate clinical follow-up for analysis. 19 of 44 (43.2%) patients treated with genomically guided therapy attained a PFS ratio ≥ 1.3 vs. 3 of 57 (5.3%) treated with non-genomically guided therapy (p < 0.0001). Similarly, overall PFS ratios (irrespective of cutoff) were higher for patients with genomically guided therapy vs non-genomically guided therapy (p = 0.05). Further, patients treated with genomically guided therapy had a superior median PFS compared to those treated with non-genomically guided therapy (86 days vs. 49 days, p = 0.005, H.R. = 0.55, 95% C.I.:0.37-0.84). Conclusion: Patients with refractory metastatic cancer who receive genomically guided therapy have improved PFS ratios and longer median PFS compared to patients who do not receive genomically guided therapy.
AB - Patients and methods: Patients with metastatic solid tumors who had progressed on at least one line of standard of care therapy were referred to the Indiana University Health Precision Genomics Program. Tumor samples were submitted for DNA & RNA next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry for actionable targets. A multi-disciplinary tumor board reviewed all results. For each patient, the ratio of progression-free survival (PFS) of the genomically guided line of therapy divided by the PFS of their prior line was calculated. Patients whose PFS ratio was ≥ 1.3 were deemed to have a meaningful improvement in PFS. Results: From April 2014-October 2015, 168 patients were evaluated and 101 patients achieved adequate clinical follow-up for analysis. 19 of 44 (43.2%) patients treated with genomically guided therapy attained a PFS ratio ≥ 1.3 vs. 3 of 57 (5.3%) treated with non-genomically guided therapy (p < 0.0001). Similarly, overall PFS ratios (irrespective of cutoff) were higher for patients with genomically guided therapy vs non-genomically guided therapy (p = 0.05). Further, patients treated with genomically guided therapy had a superior median PFS compared to those treated with non-genomically guided therapy (86 days vs. 49 days, p = 0.005, H.R. = 0.55, 95% C.I.:0.37-0.84). Conclusion: Patients with refractory metastatic cancer who receive genomically guided therapy have improved PFS ratios and longer median PFS compared to patients who do not receive genomically guided therapy.
KW - Genomics
KW - Next-generation sequencing
KW - Personalized medicine
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=84984906761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984906761&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.10606
DO - 10.18632/oncotarget.10606
M3 - Article
C2 - 27447854
AN - SCOPUS:84984906761
VL - 7
SP - 56491
EP - 56500
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 35
ER -